☆
Watchlist
Log in
Sign-up
Emvision Medical Devices Ltd (emv) Logo

Emvision Medical Devices Ltd (EMV)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

EMV Chart

Snapshot

EMV's Principal Activity is the research and development of medical imaging and diagnostic technology previously licensed and subsequently acquired from Uniquest Pty Limited, for the purpose of commercialising a portable medical device for stroke diagnosis and monitoring as well as other medical imaging needs.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -31.43%
vs ASX 200 (1yr) -35.39%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 851 of 2,408
Sector Rank 57 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies CAU / 4DX / RCE
EPS -$0.101
DPS $0.00
Book Value Per Share $0.14

Broker Consensus

EMV is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

EMvision Medical Devices Limited (EMV) is focused on the development and commercialisation of medical imaging technology. The Company's primary focus is a portable, cost effective, non-invasive brain scanner to monitor and help with the diagnosis of brain injuries and stroke by creating rapid images of the brain at the point-of-care. The Company is developing and seeking to commercialise a cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Macquarie Park NSW 2113
Website www.emvision.com.au
Registry Link Market Services
Auditor BDO Audit Pty Ltd
Date Listed 13 Dec 2018

Upcoming Calendar (Forecasted)

Date Event
30/08/2022 Report (Prelim)
30/08/2022 Report (Annual)
23/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.
Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Phillip James Dubois Non-Executive Director Sep 2020

Dr Phillip James Dubois

Non-Executive Director

Dr Dubois is an imaging executive and neuroradiologist has joined the board as an independent Non-executive Director. Dr Dubois is a former CEO of their imaging division and served as Executive Director from 2001 to 2020. He is also the founder and former CEO and Chairman of Queensland X-Ray. Dr Dubois is currently an Associate Professor of Radiology at the University of Queensland Medical School. He has served on numerous government and radiology group bodies, including the councils of the Royal Australian and New Zealand College of Radiologists and the Australian Medical Association, and as Vice-President of the Australian Diagnostic Imaging Association. Dr Dubois is a Non executive Director of Magnetica Limited.

Dr Ronald (Ron) Peter Weinberger Chief Executive Officer,Managing Director May 2020

Dr Ronald (Ron) Peter Weinberger

Chief Executive Officer,Managing Director

Dr Weinberger has more than 20 years experience in medical research, biotechnology and commercialization. Dr Weinberger joined Nanosonics in August 2004 and was appointed as Executive Director in July 2008 then Managing Director and Chief Executive Officer December 2011 with a period as acting CEO from May 2011. From October 2013 to February 2018, Dr Weinberger was responsible for the direction of Nanosonics technology development and commercialisation strategy. He is coinventor of several of Nanosonics key technology patents.

Mr Anthony (Tony) Keane Non-Executive Director Jun 2018

Mr Anthony (Tony) Keane

Non-Executive Director

Mr Keane is an experienced business and finance executive and holds a number of independent non executive director and advisory board roles. Mr Keane also undertakes finance advisory and consultancy assignments for various business clients and previously held numerous roles with a major trading bank principally in business, corporate and institutional banking. Mr Keane is currently an Independent Non-Executive Director of National Storage Holdings Ltd, the holding company established for National Storage REIT, the first independent, internally managed and fully-integrated owner and operator of selfstorage centres listed on the ASX and director of Queensland Symphony Orchestra Holdings Ltd, Queensland's largest performing arts company and only professional symphony orchestra. He is the Chair of Risk Committee.
Mr John Keep Non-Executive Chairman,Non-Executive Director Mar 2018

Mr John Keep

Non-Executive Chairman,Non-Executive Director

Mr Keep has public company board experience as well as senior management experience in the healthcare and hospitality sectors including managing start up enterprises and medical diagnostic companies. Mr Keep led the successful restructuring and revitalization of the radiology company Queensland Diagnostic Imaging, Queensland's leading private radiology and diagnostic imaging group and at Lemarne Healthcare, a company specialising in the detection and treatment of skin cancer. Mr Keep is a director of Queensland Symphony Orchestra Holdings Ltd and a member of that company's Finance Audit and Risk Committee.

Mr Geoffrey (Geoff) Richard Pocock Non-Executive Director Mar 2018

Mr Geoffrey (Geoff) Richard Pocock

Non-Executive Director

Mr Pocock has experience as a corporate advisor and strategy consultant advising companies on commercialisation and IP management, business development, mergers and acquisitions strategy and raising equity capital from private and public equity markets. Mr Pocock is currently the principal of Polaris Consulting (WA) Pty Ltd. Mr Pocock previously spent several years as a research scientist in the biopharmaceutical industry in Australia and the United Kingdom. He is member of Risk Committee.

Mr Scott Kirkland Co-founder,Executive Director Jul 2017

Mr Scott Kirkland

Co-founder,Executive Director

Mr Kirkland has held several senior sales positions, including Head of Client Sales at Quantcast, a US-based technology company. Mr Kirkland is a co-founder of the Company and oversees its corporate affairs, commercial strategy and business development efforts.
Ms Emma Waldon Chief Financial Officer,Company Secretary N/A
Show All

Director Transactions

EMV directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
04/02/22 John Keep Buy +12,000 $2.102 $25,227 On-market trade
10/01/22 Scott Kirkland Buy +7,832 $2.56 $20,049 On-market trade
22/12/21 Scott Kirkland Buy +520,755 $0.403 $210,000 Exercise of options
22/12/21 Scott Kirkland Cancelled 79,245 $2.54 $201,282 Cancellation of securities
22/12/21 Scott Kirkland Exercise 520,755 $0.403 $210,000 Exercise of options
22/12/21 Ronald (Ron) Weinberger Buy +867,925 $0.403 $350,000 Exercise of options
22/12/21 Ronald (Ron) Weinberger Cancelled 132,075 $2.54 $335,470 Cancellation of securities
22/12/21 Ronald (Ron) Weinberger Exercise 867,925 $0.403 $350,000 Exercise of options
22/12/21 John Keep Cancelled 52,830 $2.54 $134,188 Cancellation of securities
22/12/21 John Keep Buy +347,170 $0.403 $140,000 Exercise of options
22/12/21 John Keep Exercise 347,170 $0.403 $140,000 Exercise of options
22/12/21 Anthony (Tony) Keane Buy +500,000 $0.35 $175,000 Exercise of options
22/12/21 Anthony (Tony) Keane Exercise 500,000 $0.35 $175,000 Exercise of options
22/12/21 Geoffrey (Geoff) Pocock Buy +500,000 $0.35 $175,000 Exercise of options
22/12/21 Geoffrey (Geoff) Pocock Exercise 500,000 $0.35 $175,000 Exercise of options
14/04/21 Ronald (Ron) Weinberger Buy +17,200 $2.88 $49,534 On-market trade
07/12/20 Phillip Dubois Issued 500,000 $3.34 $1,670,000 Issue of options
07/12/20 Ronald (Ron) Weinberger Issued 1,000,000 $3.34 $3,340,000 Issue of options
01/12/20 Geoffrey (Geoff) Pocock Buy +5,000 $3.30 $16,500 On-market trade
01/10/20 Phillip Dubois Buy +40,000 $2.50 $100,000 Off-market trade
04/06/19 Ryan Laws Buy +14,844 $0.38 $5,641 On-market trade
03/06/19 Ryan Laws Buy +15,156 $0.368 $5,582 On-market trade
Show All

Director Interests

The current holdings of EMV directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
John Keep 04/02/2022 347,170 1,719,500 0 N/A
Scott Kirkland 10/01/2022 3,861,987 415,000 79,245 N/A
Geoffrey (Geoff) Pocock 22/12/2021 N/A 855,000 0 N/A
Anthony (Tony) Keane 22/12/2021 100,000 500,000 0 N/A
Ronald (Ron) Weinberger 22/12/2021 1,885,125 20,000 1,000,000 N/A
Phillip Dubois 30/06/2021 N/A 47,500 500,000 N/A
Show All

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Aug 25, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Ryan Michael Laws 3,350,000 4.60%
Mr Scott Philip Kirkland 3,333,400 4.57%
Neweconomy Com Au Nominees Pty Limited <900 Account> 1,800,937 2.47%
Truebell Capital Pty Ltd <Truebell Investment Fund> 1,750,110 2.40%
Uniquest Pty Limited 1,200,000 1.65%
Glensburg Pty Ltd <Tyto Corp Pension Fund A/C> 1,100,000 1.51%
Jm Starcevich Investments Pty Ltd 1,089,000 1.49%
Dr Stuart Crozier 1,044,937 1.43%
Dr Ronald Peter Weinberger 1,017,200 1.40%
Mr Bryant James Mclarty <The Mclarty Family A/C> 1,002,500 1.38%
Mr Martin Kolev 1,000,000 1.37%
Mr Paul Raymond Brown & Mrs Angelique Susan Brown <Brown Family A/C> 990,000 1.36%
Walsh Prestige Pty Ltd <Walsh Family A/C> 900,000 1.23%
Mr Vincent Michael O'Sullivan <O'Sullivan A/C> 883,000 1.21%
Hillridge Pty Ltd 871,248 1.20%
Wakil Family Group Pty Ltd <Ron Ton Fashions P/L Rp A/C> 852,437 1.17%
Kong Pak Lim 805,500 1.10%
Pit2 Co Pty Ltd <Power Investment 2 A/C> 741,298 1.02%
Wandeera Investments Pty Ltd <Hippopotamus Superannuation Fund A/C> 735,000 1.01%
Forza Management Pty Ltd <The Forza Future A/C> 672,500 0.92%
Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 1,544 1,332 476 573 114 4,039

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Scott Kirkland 25/08/2021 3,748,400 5.20

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $2.82 30 June
2020 $1.34 30 June
2019 $0.365 28 June
EMV Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.